Plasma beta-thromboglobulin, fibrinopeptide A and B beta 15-42 antigen in relation to postoperative DVT, malignancy and stanozolol treatment.
Plasma levels of betathromboglobulin (BTG), fibrinopeptide A (FPA) and B beta 15-42 fragment, indices of platelet release, thrombin generation and plasmin activity respectively, were measured in 32 high risk patients during a double blind study of a single dose of the anabolic steroid stanozolol (50 mg IM) in the prevention of DVT after major gastro-intestinal surgery. The prevalence of malignancy and the incidence of DVT (125I fibrinogen scan) were similar in the two treatment groups. On the first postoperative day, BTG, FPA and B beta 15-42 levels were increased in most patients. Plasma BTG levels were significantly increased on the first post-operative day in patients who developed a DVT (n = 14) compared to those patients who did not (n = 18). A significant increase in FPA levels was found in the DVT group, 7 days after surgery. On the morning before surgery, plasma B beta 15-42 levels were significantly increased in patients who developed a DVT. In patients undergoing surgery for early malignancy (n = 17), we observed a pre-operative increase in FPA levels when compared to patients without malignancy. At post-operative day 7, B beta 15-42 levels were significantly increased in patients who received stanozolol (n = 15), when compared to the placebo group, suggesting that intramuscular stanozolol increases fibrinolysis in vivo.
Douglas
J T
JT
Blamey
S L
SL
Lowe
G D
GD
Carter
D C
DC
Forbes
C D
CD
D001609:Beta-Globulins / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism*; D005344:Fibrinopeptide A / Q000378:metabolism*; D005767:Gastrointestinal Diseases / Q000601:surgery; D005770:Gastrointestinal Neoplasms / Q000097:blood* / Q000601:surgery; D006801:Humans; D010446:Peptide Fragments; D011183:Postoperative Complications / Q000097:blood; D013197:Stanozolol / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D001620:beta-Thromboglobulin / Q000378:metabolism*
D001609:Beta-Globulins; D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; D001620:beta-Thromboglobulin; C033786:fibrinogen Bbeta (15-42); D005344:Fibrinopeptide A; D013197:Stanozolol; D005340:Fibrinogen